Ensysce Biosciences Inc. (NASDAQ: ENSC) stock jumped 19.32% on Wednesday to $3.15 against a previous-day closing price of $2.64. With 0.97 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.61 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.3799 whereas the lowest price it dropped to was $2.5100. The 52-week range on ENSC shows that it touched its highest point at $140.00 and its lowest point at $1.90 during that stretch. Beta for the stock currently stands at -0.11.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ENSC was up-trending over the past week, with a rise of 12.90%, but this was down by -24.46% over a month. Three-month performance dropped to -63.79% while six-month performance fell -69.99%. The stock lost -90.40% in the past year, while it has lost -96.65% so far this year.
Float and Shares Shorts:
On Oct 30, 2022, short shares totaled 0.15 million, which was 7.82% higher than short shares on Sep 29, 2022. In addition to Dr. D. Lynn Kirkpatrick Ph.D. as the firm’s Pres, CEO & Director, Mr. David C. Humphrey CPA serves as its CFO, Sec. & Treasurer.
Through their ownership of 6.64% of ENSC’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.15% of ENSC, in contrast to 0.94% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in ENSC with 5.28% of the stake, HG Vora Capital Management LLC holds 123,125 shares worth 123,125. A second-largest stockholder of ENSC, The Vanguard Group, Inc., holds 15,791 shares, controlling over 0.68% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in ENSC, holding 11,712 shares or 0.50% stake. With a 0.36% stake in ENSC, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 8,272 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.32% of ENSC stock, is the second-largest Mutual Fund holder. It holds 7,519 shares valued at 24286.0. Fidelity Extended Market Index Fu holds 0.13% of the stake in ENSC, owning 3,075 shares worth 9932.0.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, ENSC reported revenue of $0.00 and operating income of -$7.06M. The EBITDA in the recently reported quarter was -$7.14M and diluted EPS was -$4.80.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ENSC since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ENSC analysts setting a high price target of $8.00 and a low target of $8.00, the average target price over the next 12 months is $8.00. Based on these targets, ENSC could surge 153.97% to reach the target high and rise by 153.97% to reach the target low. Reaching the average price target will result in a growth of 153.97% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ENSC will report FY 2022 earnings on 03/30/2023. Analysts have provided yearly estimates in a range of -$0.59 being high and -$12.95 being low. For ENSC, this leads to a yearly average estimate of -$6.77. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Ensysce Biosciences Inc. surprised analysts by -$4.97 when it reported -$5.13 EPS against a consensus estimate of -$0.16. The surprise factor in the prior quarter was -$0.07. Based on analyst estimates, the high estimate for the next quarter is -$0.14 and the low estimate is -$2.04. The average estimate for the next quarter is thus -$1.09.
Summary of Insider Activity:
Insiders traded ENSC stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 2 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 97,000 while 0 shares were sold.